ASX:RAP

Stock Analysis Report

Executive Summary

ResApp Health Limited develops digital healthcare solutions to assist doctors and allow patients to diagnose and manage respiratory disease.

Snowflake

Fundamentals

Exceptional growth potential with excellent balance sheet.

Share Price & News

How has ResApp Health's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

15.4%

RAP

2.1%

AU Healthcare Services

1.7%

AU Market


1 Year Return

78.6%

RAP

123.9%

AU Healthcare Services

10.3%

AU Market

Return vs Industry: RAP underperformed the Australian Healthcare Services industry which returned 123.9% over the past year.

Return vs Market: RAP exceeded the Australian Market which returned 10.3% over the past year.


Shareholder returns

RAPIndustryMarket
7 Day15.4%2.1%1.7%
30 Day82.9%9.6%-0.4%
90 Day141.9%9.6%-0.1%
1 Year78.6%78.6%125.1%123.9%16.7%10.3%
3 Year-20.2%-20.2%44.2%41.1%36.7%18.4%
5 Year2243.9%2243.9%505.4%452.1%50.9%16.9%

Price Volatility Vs. Market

How volatile is ResApp Health's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is ResApp Health undervalued compared to its fair value and its price relative to the market?

33.81x

Price to Book (PB) ratio


Share Price vs. Fair Value

Undervalued: Insufficient data to calculate RAP's fair value to establish if it is undervalued.

Significantly Undervalued: Insufficient data to calculate RAP's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: RAP is unprofitable, so we can't compare its PE Ratio to the Healthcare Services industry average.

PE vs Market: RAP is unprofitable, so we can't compare its PE Ratio to the Australian market.


Price to Earnings Growth Ratio

Low PEG Ratio: Insufficient data to calculate RAP's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: RAP is overvalued based on its PB Ratio (33.8x) compared to the AU Healthcare Services industry average (7.9x).


Next Steps

Future Growth

How is ResApp Health forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

95.9%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: RAP is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.3%).

Earnings vs Market: RAP is forecast to become profitable over the next 3 year, which is considered above average market growth.

High Growth Earnings: RAP's loss is forecast to worsen by 0% next year.

Revenue vs Market: RAP's revenue (94.4% per year) is forecast to grow faster than the Australian market (3.6% per year).

High Growth Revenue: RAP's revenue (94.4% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

High Future ROE: RAP's Return on Equity is forecast to be very high in 3 years time (92.6%).


Next Steps

Past Performance

How has ResApp Health performed over the past 5 years?

-33.7%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: RAP is unprofitable, and losses have increased over the past 5 years at a rate of -33.7% per year.

Accelerating Growth: Unable to compare RAP's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: RAP is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare Services industry (7.9%).


Return on Equity

High ROE: RAP has a negative Return on Equity (-70.76%), as it is currently unprofitable.


Return on Assets

ROA vs Industry: RAP is currently unprofitable, so its Return on Assets is negative.


Return on Capital Employed

ROCE Improving: RAP is currently unprofitable, so its Return on Capital Employed is negative.


Next Steps

Financial Health

How is ResApp Health's financial position?


Financial Position Analysis

Short Term Liabilities: RAP's short term assets (A$7.5M) exceeds its short term liabilities (A$1.7M)

Long Term Liabilities: RAP's short term assets (7.5M) exceeds its long term liabilities (39.7K)


Debt to Equity History and Analysis

Debt Level: RAP is debt free.

Reducing Debt: RAP has not had any debt for past 5 years.


Balance Sheet

Inventory Level: RAP has a low level of unsold assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if RAP's debt is covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: RAP has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: RAP has less than a year of cash runway if free cash flow continues to reduce at historical rates of -21% each year


Next Steps

Dividend

What is ResApp Health's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%2.5%markettop25%5.6%industryaverage1.0%forecastin3Years0%

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: Unable to evaluate RAP's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate RAP's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if RAP's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if RAP's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of RAP's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.


Next Steps

Management

What is the CEO of ResApp Health's salary, the management and board of directors tenure and is there insider trading?

2.0yrs

Average board tenure


CEO

Tony Keating 0

4.3yrs

Tenure

AU$290,039

Compensation

Dr. Anthony Keating, also known as Tony, has been Chief Executive Officer and Managing Director of ResApp Health Limited since July 2, 2015. Dr. Keating served as a Director of Commercial Engagement for En ...


CEO Compensation Analysis

Compensation vs. Market: Tony's total compensation ($USD195.81K) is about average for companies of similar size in the Australian market ($USD457.60K).

Compensation vs Earnings: Tony's compensation has been consistent with company performance over the past year.


Board Age and Tenure

2.0yrs

Average Tenure

Experienced Board: RAP's board of directors are not considered experienced ( 2 years average tenure), which suggests a new board.


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown


Management Team

  • Clas Källander

    Founder and Director of R&D of Cavidi AB

    • Tenure: 0yrs
    • Compensation: AU$108.72k
  • Nicki Farley (43yo)

    Company Secretary

    • Tenure: 6.9yrs
  • Tony Keating

    CEO, MD & Director

    • Tenure: 4.3yrs
    • Compensation: AU$290.04k
  • Brian Leedman

    Vice President of Corporate Affairs

    • Tenure: 0yrs
    • Compensation: AU$190.18k
  • Udantha Abeyratne

    Chief Scientist & Scientific Advisor

    • Tenure: 0yrs
  • Paul Porter

    Scientific Advisor

    • Tenure: 0yrs
  • Kay Taylor

    Vice President of Strategic Development & Operations

    • Tenure: 0yrs

Board Members

  • Roger Aston (63yo)

    Non-Executive Chairman

    • Tenure: 4.3yrs
    • Compensation: AU$90.00k
  • Joe Kvedar

    Member of Industry Advisory Board

    • Tenure: 0.3yrs
  • Nathan Edmund Buzza

    Non-Executive Director

    • Tenure: 1.8yrs
    • Compensation: AU$55.00k
  • Chris Ntoumenopoulos

    Non-Executive Director

    • Tenure: 4.8yrs
    • Compensation: AU$55.00k
  • Naomi Fried

    Member of Industry Advisory Board

    • Tenure: 0.3yrs
  • Tony Keating

    CEO, MD & Director

    • Tenure: 4.3yrs
    • Compensation: AU$290.04k
  • Udantha Abeyratne

    Chief Scientist & Scientific Advisor

    • Tenure: 0yrs
  • Paul Porter

    Scientific Advisor

    • Tenure: 0yrs
  • Philip Currie

    Member of Scientific Advisory Board

    • Tenure: 2.2yrs
  • Scott Claxton

    Member of Scientific Advisory Board

    • Tenure: 0.8yrs

Company Information

ResApp Health Limited's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: ResApp Health Limited
  • Ticker: RAP
  • Exchange: ASX
  • Founded: 2014
  • Industry: Health Care Technology
  • Sector: Healthcare
  • Market Cap: AU$261.096m
  • Shares outstanding: 696.26m
  • Website: https://www.resapphealth.com.au

Location

  • ResApp Health Limited
  • 100 Creek Street
  • Level 12
  • Brisbane
  • Queensland
  • 4000
  • Australia

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
RAPASX (Australian Securities Exchange)YesOrdinary SharesAUAUDJan 2005
RAPCHIA (Chi-X Australia)YesOrdinary SharesAUAUDJan 2005
NUGDB (Deutsche Boerse AG)YesOrdinary SharesDEEURJan 2005

Biography

ResApp Health Limited develops digital healthcare solutions to assist doctors and allow patients to diagnose and manage respiratory disease. The company delivers mobile software apps in various clinical se ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/17 10:31
End of Day Share Price2019/10/17 00:00
Earnings2019/06/30
Annual Earnings2019/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.